Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pritumumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Nascent Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
Nascent Biotech & HypoSpray Pharma Collaborate on Proprietary Transdermal Delivery System
Details : The collaboration aims to develop an alternative delivery mechanism for patients who can benefit from ACA-11 (pritumumab), Nascent's lead monoclonal antibody cancer treatment asset, for Brain Cancer.
Brand Name : ACA-11
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 19, 2024
Lead Product(s) : Pritumumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Nascent Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?